Urinary Tract Infection
A staged clinical reasoning case
Before you begin
This fictional composite case progresses through eight clinical decisions. Choose a response before the reasoning appears. The activity is unscored and takes approximately 15–20 minutes.
Later findings remain hidden until you complete the current stage.
Case debrief
The case progressed from localized cystitis to febrile upper-tract infection. The key prescribing problem was not simply whether the organism was susceptible. Effective treatment also required adequate exposure at the infection site, attention to renal function and drug interactions, and timely reassessment when the clinical syndrome changed.
| Decision point | Localized cystitis | Clinical progression | Implication |
|---|---|---|---|
| Anatomic site | Dysuria, frequency, urgency, and suprapubic discomfort without systemic findings | Fever, flank pain, vomiting, and costovertebral-angle tenderness | A new upper-tract syndrome requires a different drug and severity assessment |
| Drug exposure | High urinary concentrations may be sufficient | Therapeutic renal-parenchymal and systemic exposure is required | In vitro susceptibility cannot compensate for inadequate tissue penetration |
| Patient factors | Reduced kidney function, warfarin therapy, and prior fluoroquinolone toxicity constrain common options | Vomiting, hypotension, and prior fluoroquinolone tendon injury further limit therapy | Selection must integrate the pathogen, patient, drug, and infection site |
| Stewardship | Use the narrowest effective option and establish follow-up | Escalate promptly when the syndrome and severity change | Narrow and convert to oral therapy when clinical response and susceptibility allow |
Clinical reasoning priorities
- Localize the infection before choosing the drug. Bladder infection and pyelonephritis require different tissue exposure.
- A laboratory report of susceptibility predicts activity under test conditions; it does not prove that the prescribed regimen reaches the infected tissue.
- Reduced kidney function can change drug eligibility, dose, or interval and can increase toxicity risk.
- Trimethoprim-sulfamethoxazole can increase warfarin effect and requires a deliberate anticoagulation-monitoring plan when it is used.
- Failure to improve should trigger reassessment of diagnosis, adherence, absorption, resistance, complications, and source control rather than automatic broadening.
- When the patient improves and an active oral option reaches the infection site, IV-to-oral conversion and the shortest supported duration reduce unnecessary exposure.
Differential diagnosis
Dysuria and urinary frequency support cystitis, but vaginal symptoms should prompt evaluation for vaginitis, and exposure risk may require testing for urethritis or sexually transmitted infection. Flank pain can also occur with nephrolithiasis or obstruction. Persistent fever, severe unilateral pain, recurrent infection with the same organism, or failure of active therapy should raise concern for an obstructed collecting system, abscess, or another nidus requiring imaging and source control (Durham, 2026; Infectious Diseases Society of America [IDSA], 2025).
References
Durham, S. H. (2026). Urinary tract infections. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed.). McGraw Hill.
Infectious Diseases Society of America. (2025). IDSA 2025 guideline update on complicated urinary tract infections. https://www.idsociety.org/practice-guideline/complicated-urinary-tract-infections/
Sandoz Inc. (2024). Nitrofurantoin monohydrate/macrocrystals capsules: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ba9a729-a73a-4a13-a336-0284cc8a67e1
Ratliff, A., & Oliphant, C. (2026). Patient assessment, antimicrobial selection, and stewardship. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed.). McGraw Hill.
U.S. Food and Drug Administration. (2024). Bactrim DS (sulfamethoxazole and trimethoprim) tablets: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/017377s084lbl.pdf